Cardinal Capital Management Inc. Purchases 11,039 Shares of Becton, Dickinson and Company $BDX

Cardinal Capital Management Inc. grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.6% during the second quarter, HoldingsChannel.com reports. The firm owned 178,421 shares of the medical instruments supplier’s stock after purchasing an additional 11,039 shares during the period. Cardinal Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $27,000,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Becton, Dickinson and Company by 4.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock worth $122,403,000 after purchasing an additional 26,671 shares during the last quarter. Cooke & Bieler LP lifted its holdings in Becton, Dickinson and Company by 27.2% during the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after buying an additional 240,673 shares during the period. KLP Kapitalforvaltning AS grew its position in shares of Becton, Dickinson and Company by 61.2% in the 4th quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock valued at $33,493,000 after buying an additional 65,500 shares during the last quarter. Finally, Third View Private Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at about $4,992,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Up 0.9%

Shares of Becton, Dickinson and Company stock opened at $181.28 on Wednesday. The stock’s 50-day moving average is $155.80 and its 200 day moving average is $161.85. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The firm has a market cap of $49.95 billion, a price-to-earnings ratio of 54.60, a PEG ratio of 12.66 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,189 shares of company stock valued at $765,661 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada raised their price objective on Becton, Dickinson and Company from $175.00 to $180.00 and gave the stock a “sector perform” rating in a research report on Friday. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average target price of $185.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.